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ABSTRACT
Biomedical Application Teams are funded by the National 
Aeronautics and Space Administration for the purpose of 
applying aerospace technology to the solution of significant 
problems in biomedical research and clinical medicine. The 
Team at Stanford University Medical School is part of the 
Division of Cardiology and participates in all phases of the 
technology transfer process including: identification of 
significant biomedical problems, matching them with appro­ 
priate aerospace solutions, testing the new technology in the 
laboratory and clinical environment and finally, being the 
link to the medical device industry for commercially pro­ 
ducing the technology. The underlying philosophy and gen­ 
eral approach by which aerospace engineering and scientific 
expertise can be used to solve biomedical instrumentation 
problems is discussed. The methods by which the Teams 
accelerate the diffusion of new technology from aerospace- 
related research to medical applications are reviewed. Speci­ 
fic examples of successful transfers are presented to illustrate 
the many phases of the technology transfer process and the 
need for a multidisciplinary, team approach. Innovative 
technology derived from aerospace-related research is pro­ 
viding the physician with new and better instrumentation for 
medical research and patient care.
INTRODUCTION
In the Space Act of 1958 Congress directed NASA to "pro­ 
vide for the widest practical and appropriate dissemination of 
information concerning its activity and the results thereof." ' 
Following this mandate, NASA established a Technology 
Utilization Program to apply its technology to problems in 
such diverse areas as industry, transportation, communica­ 
tions, housing, and energy. Because of the special need "to 
bridge" the gap between engineering and medicine, NASA 
subsequently established Biomedical Applications Teams 
(BATeams) affiliated with major medical institutions. There 
are BATeams located at the following institutions:
1. Stanford University School of Medicine, 
Cardiology Division
701 Welch Road, Suite 3301 
Palo Alto, CA 94304
2. Research Triangle Institute 
P.O. Box 12194 
Research Triangle Park, NC 27709
3. University of Wisconsin 
1500 Johnson Drive 
Madison, Wl 53706
The Stanford BATeam began in June, 1971 and is part of the 
Division of Cardiology at the Stanford University School of 
Medicine, Stanford, CA. The Team consists of scientists, 
physicians, and engineers who work in close cooperation 
with the NASA Field Centers and in particular, with the bio­ 
medical and engineering personnel at the NASA-Ames 
Research Center, Moffett Field, CA. Initially, emphasis was 
placed on the solution of important problems in the diagno­ 
sis and treatment of cardiovascular diseases. Consequently, 
applications addressed instrumentation problems in electro- 
cardiography, cardiac catheterization, biomedical electrodes, 
and ultrasonic cardiac imaging. More recently, the Team has 
found applications for space technology in a wide range of 
medical specialties including: neurosurgery, orthopedics, 
communicative disorders, pediatrics, radiology, ophthalmol­ 
ogy, and neurology.
THE TECHNOLOGY TRANSFER PROCESS
The overall goal of the Biomedical Technology Transfer 
Program is the solution of significant technological problems 
which are impeding progress in medical research and clinical 
practice. To reach this goal, the following intermediate 
objectives must be met:
1. Identification of significant medical problems 
amenable to technological solution.
* Stanford University School of Medicine 
Stanford, CA 94305
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2. Selection of the appropriate NASA technology which 
may have been developed for other purposes.
3. Adaptive engineering to meet the medical 
requirements.
4. Demonstration of technical and medical feasibility.
5. Commercial transfer to the medical device industry 
to permit widespread utilization.
PROBLEM IDENTIFICATION AND SELECTION
The term "technology/' as used here, is broadly defined to 
include the hardware, software, and engineering expertise 
which has been an integral part of aerospace research and 
development. Technology includes scientific instruments, 
unique test facilities, computer programs, technical reports, 
research results, and new materials developed for special 
aerospace applications. Of greater importance, however, are 
the human resources (the scientific and engineering expertise, 
and spirit of cooperation) which permit the free exchange of 
ideas so necessary to the identification and implementation 
of solutions.
There are many ways in which technology developed through 
the space program can be applied or transferred to solving 
biomedical problems. No single approach to transferring 
technology is applicable in all situations; however, the 
following is the general approach most frequently used by 
BATeams.
A team representative (physician, engineer or biomedical 
engineer) confers with the medical scientist or clinician who 
has requested assistance with a specific technical problem. At 
this initial meeting a Problem Statement is developed which 
includes the following: the general medical background; 
specific technical needs; engineering constraints and specifi­ 
cations; facilities, staff, and funding available for imple­ 
mentation; existing solutions and their deficiencies; and 
selected literature references. The Problem Statements are 
then evaluated by the Team to ensure that they meet the 
following criteria:
A. There is no satisfactory solution currently available 
from industry.
B. The problem can be specified in terms which made it 
amenable to a solution derived from aerospace 
technology.
C. Solution of the problem would, make a significant 
contribution to medical research or clinical practice.
D. There is sufficient interest on the part of the medical 
device industry to anticipate their early involvement 
and cost-sharing in either the feasibility demonstration 
or later developmental stages.
If a problem meets these criteria, the next step is to identify 
NASA hardware, software, or engineering expertise relevant 
to the problem. First, a computer search of the aerospace 
data banks, which may be accessed through one of NASAs 
six Industrial Applications Centers, is performed. These on­ 
line computer searches utilize the NASA Scientific and 
Technical Information Facility in Maryland which contains 
more than a million documents, articles, and translations ab­ 
stracted from the scientific and technical aerospace reports, 
the international aerospace abstracts, computer program 
abstracts, tech briefs, and many other publications. Next, 
the Team contacts NASA personnel who have done research 
or project work related to the specific problem requirements. 
These NASA engineers are contacted through the Field 
Centers' Technology Utilization Offices. The problem state­ 
ment, formulated during the initial interview, is circulated 
among scientists and engineers who have been selected by the 
BATeam, the Technology Utilization Officers at the individ­ 
ual field centers, or by program managers at NASA Head­ 
quarters in Washington^D.C.
All potentially relevant technology that is identified by these 
searches is evaluated by the BATeam to determine whether a 
promising solution has been found. These potential solutions 
are then presented to the problem originator along with the 
supporting NASA data and documents.
Yet another approach to transferring NASA technology to 
medicine is to identify an instrument already developed for 
an aerospace application and to find a new use for it in the 
medical field. Usually significant modification and human 
factors engineering are needed to satisfy the requirements for 
use in the medical application. Assuming that an appropriate 
application can be found, this approach has the following ad­ 
vantages: technical feasibility has already been demonstrated 
and only the medical feasibility need be evaluated; since the 
instrument already exists, much time has been saved in pro­ 
totype development; and it is possible that the manufacturer 
of the instrument for the specialized aerospace application 
will also be interested in making it commercially available for 
medical applications.
ADAPTIVE ENGINEERING
Instrumentation originally designed for the space program 
usually needs to be modified or re-engineered to optimize it 
for its new application in the research laboratory or clinical 
setting. The problem originator often requires engineering 
support to make these modifications. The Team assists the 
medical investigator in obtaining funding from either NASA, 
a potential manufacturer, or one of the federally funded 
health agencies.
DEMONSTRATION OF FEASIBILITY
Demonstration of technical and medical feasibility for any 
new instrument is costly and time-consuming. The NASA 
Technical Utilization (TU) program alone cannot fund
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clinical or preclinical trials; and therefore, the Team and the 
problem originator must solicit support from the National 
Institutes of Health, the Rehabilitation Services Administra­ 
tion, the Veterans Administration, or the medical device 
industry. For example, if NASA technology is being utilized 
in a new instrument for diagnosing a cardiac abnormality, 
then the medical investigators would seek support from the 
National Heart, Lung, and Blood Institute within the Nation­ 
al Institute of Health (NIH) for laboratory studies and 
clinical trials. In addition to broadening the source of fund­ 
ing for a given project, the requirement for support by a non- 
NASA governmental agency helps to ensure that the tech­ 
nology being transferred will meet a widely perceived need. 
After successful clinical trials, presentations are made at 
major medical and engineering symposia and published in 
biomedical journals in order to gain acceptance of the new 
technology by the medical community. Even when each of 
these objectives has been met, the new biomedical device 
cannot achieve widespread use until it becomes commercially 
available.
COMMERCIALIZATION
Widespread use of a device resulting from the Technology 
Transfer Program requires the assistance of the medical 
device industry. Before a new technology can achieve com­ 
mercial success, it must meet the following criteria:
1. The NASA technological solution must provide an 
improvement in medical treatment or diagnosis.
2. The solution must provide a reduction in health care 
cost or a significant improvement in the quality of care.
3. The medical market must be large enough to warrant 
the necessary capital risk by industry.
4. The device must be manufacturable at a cost which 
will permit penetration into the market.
5. The identified manufacturer must be able to bear most 
of the future developmental costs.
The initial step in the commercialization process is to de­ 
termine the potential market for the new device. Market data 
is accumulated by contacts with potential manufacturers and 
through a formal market survey conducted by the Illinois 
Institute of Technology Research Institute, which is under 
contract to NASA for this purpose. If the market survey is 
favorable, proposals are solicited from manufacturers to pro­ 
ceed with further development and commercialization. The 
Team then selects the most suitable commercial manufac­ 
turer based on evidence of understanding of the technical 
problems, previous experience with the requisite technologies, 
availability of resources for quality control, and large-scale 
manufacturing and marketing resources.
EXAMPLES OF COMPLETED 
MEDICAL TECHNOLOGY TRANSFERS
The following three exafnples illustrate both the scope of the 
Stanford BATeam program, and the evolution of technology 
transfer from the problem definition stage to the complete 
commercial transfer. In each example the medical back­ 
ground and need, the NASA technological solution, and the 
current status of the transfer are described.
1. Biomedical Electrodes
A biomedical electrode is an electrically conductive interface 
for the recording of physiological signals. The most familiar 
examples of biomedical electrodes are the plates and suction 
cups used in recording a routine electrocardiogram. Similarly, 
adhesive-backed surface electrodes are used extensively in 
monitoring the cardiac and respiratory signals of patients in 
hospital intensive care units. The seemingly simple task of 
obtaining dependable long-term electrical signals from 
patients has proven to be a difficult bioengineering problem. 
Haslam and Bruner have reported that half of the monitoring 
system failures in the typical hospital are the result of 
difficulties with leads and electrodes.^
In order to stimulate advances in electrode technology, the 
BATeam held a conference in 1973 attended by 200 special­ 
ists in representing academia, government, industry, and 
medicine. The proceedings of this conference were edited 
and published^ and provided a comprehensive review of 
the subject, clarifying the needs and deficiencies in present 
technology, as well as suggesting improvements and stimulat­ 
ing further research to advance the state of electrode tech­ 
nology. The Conference stimulated changes in the types of 
materials and designs used in electrode manufacture. One 
electrode manufacturer subsequently developed and market­ 
ed a low-profile, soft, conformable surface electrode based 
on a presentation made by a NASA engineer. The elec­ 
trode is made by impregnating an elasticized nylon mesh 
cloth with conductive silver particles and is backed with an 
adhesive silicon sponge rubber disc (Figure 1). A tab of the 
conductive nylon is then attached to a lead wire with a 
conductive epoxy. The manufacturer who attended the 
NASA-sponsored conference has been marketing the elec­ 
trode since 1975. Because these electrodes are soft and easily 
conform to the body surface, they permit continuous moni­ 
toring with minimal patient discomfort. This type of elec­ 
trode has also been applied in rehabilitative medicine.
2. Biotelemetry for Pediatric Gait Analysis
Cerebral palsy is a crippling neurological disease which 
manifests itself in early childhood. It results in varying 
degrees of muscular spasticity and loss of coordination. The 
inappropriate muscular contractions and loss of coordination 
frequently result in severe walking impairment. Although 
there is no cure for the disease, accuate diagnosis of the in­ 
dividual patient's gait abnormality is essential to the per­ 
formance of corrective orthopedic surgery.
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Normal ambulation is a complex activity requiring the co­ 
ordinated contraction and relaxation of many individual 
muscle groups in the legs. In analyzing walking abnormalities, 
physical therapists make use of the electromyographic 
(EMG) signals associated with muscle contraction. In adults 
and large children it is feasible to attach surface electrodes 
over the muscles to be examined and run wires from those 
electrodes to a recording device. Children with cerebral 
palsy, who are candidates for corrective surgery, are fre­ 
quently only 3-4 years old and a bundle of wires trailing 
behind the child may, itself, affect his already unstable gait 
pattern. In addition, since the child is aware of being moni­ 
tored by the physician or therapist, he may modify his usual 
walking pattern and give a false impression of his gait ab­ 
normality. The problem posed to NASA, therefore, was to 
devise a monitoring system which would allow the recording 
of the EMG signal in small children with cerebral palsy with­ 
out interfering, either physically or psychologically, with 
their natural ambulatory pattern.
The NASA solution is represented diagrammatically in 
Figure 2. Multiple individual radio transmitters (decorated as 
lady-bugs) are utilized. The transmitter circuit was designed 
by a NASA engineer to minimize external electromagnetic 
interference, maximize battery life, and provide a wide band­ 
width for both research and clinical applications. This 
approach provided the following advantages over earlier 
instrumentation:
1 . The size and weight of the transmitters were 
more suitable for evaluating younger children.
2. Use of individual transmitters simplified 
instrumenting the patient, thus reducing 
the time required for the examination.
3. The individual, self-contained transmitters 
eliminated earlier problems with cables and 
connectors and permitted adding or subtracting 
units as needed for the individual patient.
An 8-channel system is now in use at the Children's Hospital 
at Stanford, Palo Alto, CA. Up to six channels of EMG data 
can be recorded simultaneously. The other two channels are 
used for foot switch information, indicating either the swing 
or weight-bearing phase of gait. The system is now being 
manufactured commercially and a design which makes in­ 
creased use of integrated circuitry to further reduce size and 
weight is under consideration.
3. Intracranial Pressure Monitorying.
In cases of head -trauma, brain tumor, cerebral infection, and 
hydrocephalus, the pressure Inside the head, or intracranial 
pressure (ICPLcan become dangerously elevated. Elevation 
in ICP can lead to reduced blood flow to the brain, resulting 
in irreversible damage or death within a few minutes. Opti­ 
mal management of the brain-injured patient, therefore,
necessitates continuous and accurate monitoring of ICP. The 
measurement of ICP is particularly useful in deciding which 
medical and surgical therapies are appropriate. The most 
commonly used technique for monitoring ICP utilizes a fluid- 
filled catheter in direct communication with the cerebro- 
spinal fluid and coupled externally to a pressure transducer. 
One of the problems associated with this technique is that 
the catheter provides a direct pathway for brain infection, 
limiting the monitoring period to at most a few days.
In cooperation with the Departments of Neurosurgery and 
Anesthesiology at Stanford University Medical School, 
NASA-Ames Research Center engineers have designed an 
epidural pressure transducer/transmitter for continuous 
monitoring of ICP. The pressure transducer is adapted from a 
design originally used by NASA for the measurement of air 
pressure over the wings of experimental aircraft during wind 
tunnel tests. Likewise, the inductively-powered biotelemetry 
electronics are based on developments within the NASA Life 
Sciences Program for monitoring man and animals in space.
As shown in Figure 3, the neurosurgeon inserts the ICP 
transducer/transmitter through a small hole in the skull and 
secures it in a mounting fixture. The transmitter is locked in 
place so that its transducer diaphragm is in direct contact 
with the dura, a protective membrane which surrounds the 
brain. The scalp is sutured closed over the unit so that there 
is no direct pathway for infection. Changes in ICP are con­ 
verted into a frequency and transmitted to an external 
receiver (not shown in the figure).
Clinical trials are in progress at the Stanford University. The 
ICP monitor is inserted at the end of a neurosurgical pro­ 
cedure and patients are monitored continuously in the 
Intensive Care Unit. The approach has proven to be safe and 
reliable gnd a medical device manufacturer has been licensed 
by NASA to produce the next generation system for wide­ 
spread clinical use.
ADDITIONAL BIOMEDICAL EXAMPLES 
OF TECHNOLOGY TRANSFER
Each of the preceding examples are completed technology 
transfers which have already reached the commercialization 
stage. The following are short descriptions of additional 
Stanford BATeam projects which are in the earlier stages of 
transfer.
1. Versatile Portable Speech Prosthesis
This is a communications device for use in rehabilitative 
medicine by nonvocal, handicapped patients. The system 
consists of a user interface module, a microprocessor-based 
computer system, and a synthesized speech output device. 
Extensive use is made of aeronautical communications 
technology developed by NASA during investigations of 
synthesized speech in advanced aircraft. The device has been 
designed to minimize training time, to permit the user to
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develop his own vocabulary, to adapt to a wide range of user 
physical disabilities, to permit rapid sentence construction, 
and to provide improved speech intelligibility. The system 
will be used initially with wheelchair-confined cerebral palsy 
patients at the Children's Hospital at Stanford; however, the 
versatility of its design makes it potentially applicable to 
patients with multiple sclerosis, Parkinson's disease, muscular 
dystrophy, and stroke.
2. Radiographic Spatial Frequency Multiplexing
This is an x-ray filtering and decoding technique for enhanc­ 
ing the contrast of selected body tissues and organs. The 
technique holds promise for imaging soft tissue tumors 
otherwise hidden by overlying bone as well as permitting ex­ 
amination of internal organs using peripheral injections of 
low doses of contrast materials. The x-ray decoding system is 
an application of NASA technology developed for the Earth 
Resources Technology Satellite. At present, only laboratory 
animal studies have been performed; it is anticipated that 
patient studies will commence this year.
3. Pediatric Roentgen Densitometry
The Roentgen Densitometer is a diagnostic x-ray device de­ 
signed for screening newborn infants for intracardiac shunts. 
The system consists of a standard x-ray source coupled to an 
array of solid-state gamma detector diodes which were 
developed during NASA-sponsored solar cell research for 
powering satellites. When an infant is born with a heart 
murmur or develops cyanosis, it may be difficult to tell 
whether he has a surgically correctable congenital heart 
defect or some other nonsurgical problem. To resolve this 
diagnostic dilemma, cardiac catheterization may be necess­ 
ary. Cardiac catheterization not only requires elaborate instru­ 
mentation and technical personnel, but involves some risk to 
the infant. In contrast, roentgen densitometry, which re­ 
quires only the peripheral injection of a small amount of 
radiopaque material, can be performed in the newborn 
nursery with far less risk and expense. Used as a screening 
device, it could reduce the number of catheterizations per­ 
formed. Studies in over 50 infants using a prototype device 
were successfully completed and three second-generation 
densitometers are being fabricated for evaluation at major 
university cardiology departments.
4. Nanophor
This is a laboratory instrument which uses an electric field 
for separating and identifying medically important serum 
proteins. This instrument's initial development was funded in 
part by NASA for use in analyzing the serum proteins of 
Apollo astronauts. It is an improvement over existing electro- 
phoresis instruments in that it permits analysis of nanogram 
quantities of serum and incorporates a multiple-sample appli­ 
cator to speed up the analysis and improve the accuracy of 
the test. NASA has recently granted a license for the com­ 
mercial manufacture of this new instrument.
5. Liquid Circulating Garments
Temperature-regulated garments were developed for astro­ 
nauts to permit them to withstand the temperature extremes 
associated with extravehicular activity during spaceflight. 
The following medical applications have been proposed and 
are currently under evaluation:
1. Elevation of body temperature in the treatment of 
metastatic cancer, both alone and in conjunction 
with chemotherapy.
2. Surface cooling prior to cooling by cardiopulmonary 
bypass for certain types of heart and brain surgery.
3. Lowering of body temperature in patients with 
diffuse brain injury to reduce metabolic rate and 
oxygen requirements.
4. Surface cooling of the breasts prior to thermography 
to aid in the detection of breast cancer.
5. Applications in such rare diseases as hyperkeratosis 
and "burning limb" syndrome.
6. Regulation of infant body temperature during surgery.
The NASA garments contain flexible heat transfer panels 
made of a polymer inscribed with tiny channels through 
which cooled or heated water is circulated.
6. Noninvasive Determination of Bone Properties
Stanford University engineers in collaboration with NASA 
scientists have developed a mechanical device for measuring 
the driving point impedance of bone. The development of 
this new instrument grew out of NASAs interest in deter­ 
mining bone demineralization caused by the zero gravity of 
space flight. In performing the test, a vibrating probe is 
placed in contact with the subject's forearm and the force 
and displacement of the bone are analyzed and used to calcu­ 
late bending ridigity and axial buckling load index, that is, 
the load or weight which the bone can support without 
fracturing. The device incorporates a microprocessor which 
permits performance of five tests complete with computer 
print-out in approximately 10 seconds. Preliminary tests in 
the Orthopedic Clinic have shown that the instrument can 
provide a useful measure of bone strength, and can readily 
detect differences between an injured and uninjured limb. 
Although further data are being obtained on the repro- 
ducibility and sensitivity of the test, the instrument promises 
to be useful in diagnosing fractures, and following the course 
of fracture healing, as well as in evaluating osteoporosis, a 
common bone disease of older patients.
CONFERENCES AND PUBLICATIONS
In addition to its daily activities in transferring technology to
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the solution of particular biomedical problems, the Stanford 
BATeam, sponsored by NASA, has conducted both national 
and international conferences addressing broader areas of 
biomedical instrumentation. The first of these conferences, 
held in 1973, was entitled "Biomedical Electrode Tech­ 
nology: Theory and Practice/' This was followed in 1975 by 
"Cardiovascular Imaging and Image Processing - Ultrasound, 
Angiography, and Isotopes/ 7 In 1976 the 'Third Inter­ 
national Symposium on Biotelemetry" was held on the 
West Coast, and most recently, the BATeam hosted the 
"Noninvasive Cardiovascular Measurements Conference" in 
September 1978. The proceedings of each of these confer­ 
ences have been compiled, edited, and published.3' 8, 9, 10 
These conferences highlight NASA technological develop­ 
ments and provide a review of related advances in biomedical 
instrumentation, as well as a forum for evaluating com­ 
petitive technologies, and identifying those areas where 
improvements are needed. In general, such conferences 
provide a means by which ". . . the technologist and the user 
can educate each other as to what each might be able to do 
and ... to reach a point where some technology can be 
transferred."^
IMPEDIMENTS TO BIOMEDICAL 
TECHNOLOGY TRANSFER
Although each of the previously described biomedical tech­ 
nology transfer projects has achieved some degree of success, 
there are many unsolved problems which tend to hinder 
the development and introduction of new biomedical tech­ 
nology. The following is a list of some of the current prob­ 
lems:
— Insufficient federal funding for biomedical technolog­ 
ical research and development
— Lack of cooperation among the various federal health 
agencies in accepting responsibility for new technolog­ 
ical developments
— Lack of a central clearing house of information about 
existing biomedical technology
— The long lag-time (1-2 years) between the identifica­ 
tion of technological break-throughs and the granting 
of funds for preliminary concept validation
— Lack of appreciation of the time span (5-10 years) re­ 
quired in taking a concept from the prototype phase to 
the point of being generally accepted by the medical 
profession
— An increasing tendency to use technology as a scape­ 
goat for rapidly rising medical costs without carefully 
weighing potential medical and cost benefits
— The potential for PDA regulations, with their attend­ 
ant documentation requirements, to over-control and 
stifle technological innovation
— The tendency on the part of federal patenting and 
licensing regulations to impede rather than promote 
commercialization
— A lack of appreciation of the technical difficulties and 
financial risks involved in commercially developing new 
technology
Though each of these problems is complex and involves 
diverse groups with their own special interests, collaborative 
solutions must be found to achieve the common goal of more 
efficient use of medical resources.
CONCLUDING REMARKS
Although technology from one field can become transferred 
or reapplied to a new discipline and for a new application by 
the slow, natural process of diffusion, successful transfer is 
frequently hindered by language, economic, and regulatory 
barriers. The transfer of technology, however, can be acceler­ 
ated through multidisciplinary and systematic efforts by Bio­ 
medical Applications Teams which act as catalysts in the 
application of NASA technology to the solution of biomed­ 
ical problems.
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Figure 1. Flexible Biomedical Electrodes Being Applied for Ambulatory 
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